Although numerous predictors of prognosis for PCa patients, such as the Gleason score and PSA, have been established, they have limited ability in predicting the time to biochemical recurrence.[101] Therefore, developing a highly accurate and specific biomarker is essential for predicting PCa prognosis and guiding its treatment. The gene discussed is KLK3; the disease is posterior cortical atrophy.